A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
A technical feasibility report on correlative studies from the investigator-initiated phase II study of pembrolizumab (Pembro) immunological response evaluation (INSPIRE).
Derek L. Clouthier,Cindy Yang,Scott Lien,Diana Gray,Ilaria Colombo,Stephanie Lheureux,Jeremy Lewin,Albiruni Ryan Abdul Razak,Anna Spreafico,Philippe L. Bedard,Marcus O. Butler,Daphne Day,Aaron R. Hansen,Trevor J. Pugh,Helen Chow,Sawako Kobori,Amanda Giesler,Pamela S. Ohashi,Lillian L. Siu +18 more
TL;DR: biomarkers of response to immune checkpoint inhibitors are needed and a biomarker-driven study to comprehensively evaluate changes in genom...
Journal ArticleDOI
A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
Herbert H. Loong,Martin E. Blackstein,Abha A. Gupta,David W. Hogg,Helen Mackay,Neesha C. Dhani,Amit M. Oza,Malcolm J. Moore,Albiruni Ryan Abdul Razak +8 more
TL;DR: ENMD-2076 is an oral Aurora A and angiogenic kinase inhibitor that hasdemonstrated the ability to abrogate tumor growth in STS.
Journal ArticleDOI
Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).
Tira Jing Ying Tan,David W. Cescon,Lisa Wang,Eitan Amir,Daniella Vieira,Kaitlyn Zammit,David Warr,Christine Elser,Marcus O. Butler,Albiruni Ryan Abdul Razak,Aaron R. Hansen,Anna Spreafico,Lillian L. Siu,Philippe L. Bedard +13 more
TL;DR: Hyperprogression of disease (HPD), a rapid acceleration of tumor growth rate (TGR) has been reported with IO in other tumor types is explored in aTNBC.
Journal ArticleDOI
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson,Enrique Sanz-Garcia,Wenjiang Zhang,ZhihuiAmy Liu,Sy Cindy Yang,Ben X. Wang,Shaofeng Liu,Shawn P. Kubli,Hal K. Berman,Thomas Pfister,Sofia Genta,Anna Spreafico,Aaron R. Hansen,Philippe L. Bedard,Stephanie Lheureux,Albiruni Ryan Abdul Razak,David W. Cescon,Mark S. Butler,Wei Xu,Tak W. Mak,Lillian L. Siu,Eric Chen +21 more
TL;DR: The association between improved PFS and ΔcholineC3 suggests a possible role for the cholinergic system in the regulation of antitumor immunity, and is the first exploratory report of serum choline levels in pan-cancer patients receiving pembrolizumab.